Analyzing Firefly Neuroscience (AIFF) & The Competition

Institutional and Insider Ownership

5.0% of Firefly Neuroscience shares are owned by institutional investors. Comparatively, 56.9% of shares of all “Prepackaged software” companies are owned by institutional investors. 8.4% of Firefly Neuroscience shares are owned by company insiders. Comparatively, 18.9% of shares of all “Prepackaged software” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Firefly Neuroscience has a beta of 3.25, meaning that its share price is 225% more volatile than the S&P 500. Comparatively, Firefly Neuroscience’s competitors have a beta of 0.45, meaning that their average share price is 55% less volatile than the S&P 500.

Valuation and Earnings

This table compares Firefly Neuroscience and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Firefly Neuroscience	$479,000.00	-$2.03 million	-1.22
Firefly Neuroscience Competitors	$2.51 billion	$326.31 million	-670.55

Firefly Neuroscience’s competitors have higher revenue and earnings than Firefly Neuroscience. Firefly Neuroscience is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Firefly Neuroscience and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Firefly Neuroscience	-73.72%	-276.50%	-133.02%
Firefly Neuroscience Competitors	-71.61%	-38.00%	-6.78%

Summary

Firefly Neuroscience competitors beat Firefly Neuroscience on 7 of the 9 factors compared.

Firefly Neuroscience Company Profile

Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytics, a software that focuses on diagnostic and treatment for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. It serves pharmaceutical companies and medical practitioners. Firefly Neuroscience, Inc. is based in Toronto, Canada.